The adhesive phenotype of neutrophils (PMN) depends largely on activating and deactivating intracellular signals regulating β2 integrin avidity for ligand. Our hypothesis is that PKA is a negative regulator of β2 integrin avidity. In this work, we examined the role of PKA in PMN αMβ2 integrin activation. Elevation of cAMP inhibited αMβ2 integrin-dependent adhesion of PMN to immune complexes (IC), but not PMA-induced adhesion. The PKA inhibitor KT5720 reversed the ability of cAMP to suppress adhesion to IC. Moreover, inhibition of PKA activity was sufficient to activate αMβ2 integrin-dependent adhesion and increase β2 integrin expression and binding of the monoclonal antibody CBRM1/5, which recognizes activated αMβ2 specifically. However, PKA activity was necessary for sustained adhesion. Disruption of A kinase-anchoring, protein-PKA binding with a cell-permeant peptide derived from the AKAP Ht31 also activated adhesion. Unlike pharmacologic inhibition of PKA, AKAP peptide-induced adhesion was PKC dependent and did not affect β2 integrin expression or CBRM1/5 binding. These data demonstrate that PKA appears to have a dual role in the mechanism regulating αMβ2 integrin avidity and adhesion.
No takes yet. Share an insight, caveat, or question.
Samuel L. Jones (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: